Natalizumab Case Study

788 Words 4 Pages
T cells also have effect on Natalizumab in patients with multiple sclerosis. Natalizumab is a monoclonal antibody that reduces the formation of acute lesions in the central nervous system. Bornsen et. al revealed the influence that natalizumab has on circulating CD4+ T cells in multiple sclerosis. The recurrence of multiple sclerosis happens when there are abnormalities in activated macrophages, CD4+ and CD8+ T cells in the central nervous system. Very-late antigen formed on surfaces of most immune system, binding to vascular cell adhesion molecule expressed on endothelial cells is important in the attachment and movement of activated macrophages, CD4+ and CD8+ T cells from the blood to the central nervous system. Also, the binding of Natalizumab antibody to VLA-4 (very- late antigen) which consist of a4 (CD49D) and b1 chain (CD29) helps in …show more content…
Natalizumab treated multiple sclerosis patients had greatly increased the formation of TNF and significantly decreased expression of IL10 in circulating CD4+ and CD8+ T cells which does not correlate between Expanded Disability Status Scale (EDSS) or the disease. Expanded Disability Status Scale (EDSS) is a method by which disability is determined in multiple sclerosis. Also, there were no contrast in the CD4+ T cell proliferation or expression of cytokine in untreated and multiple sclerosis patients treated with natalizumab and natalizumab had no serious effect on the part of proliferating CD4+ T cells or a formation of IL-17A and IFN-c in MBP-reactive CD3+ CD8 T cells. CD4+ and CD8+ T cells from patients treated with natalizumab shows levels of messenger RNA encoding TNF-a transcript. Effector T cells also have a high capacity in the production of pro-inflammatory cytokines and may result to a better pool of pro inflammatory

Related Documents